Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Source: SeekingAlpha
2026-03-19 07:44:26 ET
More on Pfizer, Astellas Pharma ADR
- Pfizer: I'm Still Expecting A Massive Rebound
- Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
- Pfizer: Cheap For A Reason
- TrumpRx drug prices aren't the lowest as president claims - report
- FTC monitoring how Big Pharma reacts to upcoming patent cliffs, official says
Read the full article on Seeking Alpha
For further details see:
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.89% G/L:
$14.75 Last:
104,314 Volume:
$15.43 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
